Ontuxizumab is a humanized rabbit monoclonal antibody designed for the treatment of cancer. It binds to endosialin (TEM1 or CD248).
Phase I trials are complete and the drug was granted orphan drug status by the FDA for sarcoma. It is currently in phase II trials for melanoma, colorectal cancer, sarcoma, and lymphoma.
This drug was developed by Morphotek and Ludwig Institute for Cancer Research.
- ^ World Health Organization (2013). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 109" (PDF). WHO Drug Information. 27 (2).
- ^ US 20100260769, Sass PM, Kline B, Nicolaides N, Grasso L, Harley S, "Endosialin binding molecules", published 2010-04-08, assigned to Morphotek Inc
- ^ Kiyohara E, Donovan N, Takeshima L, Huang S, Wilmott JS, Scolyer RA, et al. (August 2015). "Endosialin Expression in Metastatic Melanoma Tumor Microenvironment Vasculature: Potential Therapeutic Implications". Cancer Microenvironment. 8 (2): 111–8. doi:10.1007/s12307-015-0168-8. PMC 4542822. PMID 26085332.
- ^ a b "Ontuxizumab". Adis Insight. Springer Nature Switzerland AG.